Premium
Normal Infant after Treatment of Acute Myeloid Leukaemia in Pregnancy with Daunorubicin
Author(s) -
Lowenthal R. M.,
Marsden K. A.,
Newman N. M.,
Baikie M. J.,
Campbell S. N.
Publication year - 1978
Publication title -
australian and new zealand journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 0004-8291
DOI - 10.1111/j.1445-5994.1978.tb04918.x
Subject(s) - medicine , daunorubicin , myeloid leukaemia , pregnancy , myeloid , pediatrics , leukemia , genetics , biology
Summary: Daunorubicin, thioguanine and cytosine arabinoside were administered from the 17th to 34th weeks of pregnancy in a 23‐year‐old patient with acute myeloid leukaemia. The patient went into remission of her leukaemia, and a normal male infant was born after labour was induced in the 40th week. This experience supports the view that modern regimens of anti leukaemic drugs may be administered during the second and third trimesters of pregnancy without harmful effects on the foetus.